Amid much hype and interest, the U.S. Food and Drug Administration (FDA) approved Vyleesi (bremelanotide), an injection designed to improve female sexual interest arousal disorder (FSIAD) — also known as hypoactive sexual desire disorder — in premenopausal women, in June 2019.
Female sexuality is a a complex interplay of medical, psychological, situational & relationship status. Although this new medication for Female Sexual Interest/Arousal Disorder offers another option in what is actually a large armamentarium, physicians still need to be educated on female sexuality and specifically desire.
Physicians receive a paucity of sexual health education in medical school (women have only recently been perceived as sexual beings after all). Unless they take it upon themselves to specialize, doctors likely won't be writing these prescriptions.
A clinical pathway is necessary to treat women who experience everything from low sexual desire to FSIAD or anorgasmia that takes into account age, relationship length, conflict resolution, sexual abuse history, medical conditions, medications & more.
Women report more boredom in the bedroom than men. That is the female norm.
A patient of mine thought she had low sexual desire. She went to NYC for a girls weekend and came upon a man at a club to whom she was wildly attracted & ended up having amazing sex.
Did she have low sexual desire? Yes, indeed. For Her husband.
But she did not want to leave him.
#sexualdesire #boredbeds #arousal #love #lust
Maureen McGrath is a Registered Nurse and Sexual Health Educator who hosts the Sunday Night Health Show (a sex show disguised as a health show because sex is still taboo) on the Corus Radio Network in Canada. https://globalnews.ca/bc/program/sunday-night-health-show